Blowers v. Eli Lilly & Co.

100 F. Supp. 2d 1265, 2000 U.S. Dist. LEXIS 9104, 2000 WL 854428
CourtDistrict Court, D. Hawaii
DecidedJune 13, 2000
DocketCIV.00-0008ACK/FIY
StatusPublished
Cited by3 cases

This text of 100 F. Supp. 2d 1265 (Blowers v. Eli Lilly & Co.) is published on Counsel Stack Legal Research, covering District Court, D. Hawaii primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Blowers v. Eli Lilly & Co., 100 F. Supp. 2d 1265, 2000 U.S. Dist. LEXIS 9104, 2000 WL 854428 (D. Haw. 2000).

Opinion

ORDER GRANTING DEFENDANT’S MOTION TO DISMISS PLAINTIFF’S UNFAIR OR DECEPTIVE ACTS OR PRACTICES CLAIM

KAY, District Judge.

This matter stems from Hugh Blowers’ ingestion of Prozac®, an antidepressant medication manufactured by Eli Lilly and Company (“Defendant”), and Hugh’s subsequent suicide. The following tragic facts are taken from Plaintiffs’ Complaint. 1 The facts are, at this point, of course, simply allegations. For purposes of this opinion, however, the Court must assume them to be true.

Plaintiffs Norman Blowers and Naeyo Blowers (“Plaintiffs”) are the parents of Hugh Blowers. According to Plaintiffs, Hugh began taking Prozac® on May 27, 1999, battling depression and plagued by suicidal thoughts. Plaintiffs allege that prior to this time, Hugh had never attempted suicide, nor did he have a plan to take such an action. See First Am. Compl. ¶ 36.

Hugh’s psychiatrist, Dr. Forsten, warned Hugh and his parents about the anticipated side effects of Prozac®. According to Plaintiffs, however, Dr. Forsten, despite a careful reading of the warnings provided by Defendant, was unaware that close monitoring during the early period of Prozac® ingestion was necessary to minimize the risk of suicide, nor was Dr. For- *1266 sten warned that ingestion may cause aka-thisia, a condition that can trigger latent suicidal ideation to become patently active.

After several days of ingesting Prozac®, Hugh reported to his parents and friends that the drug was “messing with [his] mind” and he felt discomfort. First Am. Compl. ¶ 42. Not having any warning, neither Plaintiffs nor Dr. Forsten knew such feelings were indicative of akathisia.

On June 3, 1999, after taking only seven Prozac® pills, Hugh hanged himself.

Defendant is the developer, manufacturer, and marketer of Prozac®, and launched the international marketing of the drug in late 1987. Despite some scientific studies indicating the drug may cause some people to become violent or suicidal, Defendant never tested Prozac® to determine whether such a causal relationship truly existed prior to releasing the drug on the market. Despite Defendant’s knowledge that the drug may have caused thousands of suicides, Defendant never warned the public, prescribing physicians, or patients about such risks, claiming that there is no connection between Prozac® and suicide or violence because an independent FDA panel investigated the matter and wrote a report to that effect.

Plaintiffs allege that Defendant knew that Prozac® may induce akathisia, and failed to warn about this risk in order to better market the drug. Plaintiffs contend that had Defendant warned Dr. Forsten of the drug’s risks, measures would have been taken to prevent Hugh’s suicide. They claim that Prozac® is defective in its design, as it is unreasonably dangerous and unavoidably unsafe.

Plaintiffs filed a complaint on January 5, 2000. Plaintiffs claim the following causes of action: (1) products liability; (2) negligence; (3) unfair or deceptive acts or practices, in violation of Hawaii Revised Statutes §§ 480-2 and 480-13 and the federal consumer protection act; and (4) battery. Plaintiffs request both economic and non-economic damages, including punitive damages and treble damages under H.R.S. § 480-13(b). Plaintiffs further request this Court enjoin Defendant’s unlawful and deceptive acts and practices pursuant to H.R.S. § 480 — 13(b)(2).

Defendant filed a Motion to Dismiss Unfair or Deceptive Acts or Practices Claims on March 14, 2000. Defendant argues that the Hawaii law does not provide an unfair or deceptive acts or practices cause of action for personal injury actions. Defendant further asserts that the Federal Consumer Product Safety Act, 15 U.S.C. § 2051 et seq., does not extend to prescription drugs such as Prozac®.

Plaintiffs filed a Memorandum in Opposition on April 27, 2000. Plaintiffs contend that H.R.S. § 480-13(b) provides a cause of action for consumers who have been injured by an unfair and deceptive act or practice. Alternatively, Plaintiffs argue that they may recover property damages under the statute, as they lost the services of their son, and will ask this Court to enjoin Defendant from the sale and distribution of Prozac® as provided by H.R.S. § 480-13(b)(2). 2

Defendant filed a Reply on May 4, 2000, alleging that any non-personal injury claims are derivative from Plaintiffs’ personal injury claims, and are barred. Moreover, Defendant alleges that Plaintiffs are not “consumers” as defined by H.R.S. § 480. 3

Plaintiffs filed a Submission of Uncited Authorities Pursuant to Local Rule 7.8 on May 10, 2000.

*1267 The Court heard oral argument on May-15, 2000.

STANDARD

Motion to Dismiss

Under Rule 12(b)(6), in determining whether a motion to dismiss for failure to state a claim upon which relief can be granted, this Court must accept as true the plaintiffs allegations contained in the complaint and view them in a light most favorable to the plaintiff. Scheuer v. Rhodes, 416 U.S. 232, 236, 94 S.Ct. 1683, 1686, 40 L.Ed.2d 90 (1974); Wileman Bros. & Elliott, Inc. v. Giannini, 909 F.2d 332, 334 (9th Cir.1990); Shah v. County of Los Angeles, 797 F.2d 743, 745 (9th Cir.1986). Thus, the complaint must stand unless it appears beyond doubt that the plaintiff has alleged no facts that would entitle him to relief. Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 101-02, 2 L.Ed.2d 80 (1957); Balistreri v. Pacifica Police Dept., 901 F.2d 696, 699 (9th Cir.1988). A complaint may be dismissed as a matter of law for two reasons: (1) lack of a cognizable legal theory or (2) insufficient facts under a cognizable legal theory. Balistreri, 901 F.2d at 699; Robertson v. Dean Witter Reynolds, Inc., 749 F.2d 530, 533-34 (9th Cir.1984).

In essence, as the Ninth Circuit has stated, “[t]he issue is not whether a plaintiffs success on the merits is likely but rather whether the claimant is entitled to proceed beyond the threshold in attempting to establish his claims.” De La Cruz v. Tormey, 582 F.2d 45, 48 (9th Cir.), cert. denied, 441 U.S. 965, 99 S.Ct. 2416, 60 L.Ed.2d 1072 (1979).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Courbat v. Dahana Ranch, Inc.
141 P.3d 427 (Hawaii Supreme Court, 2006)
Akee v. Dow Chemical Co.
293 F. Supp. 2d 1140 (D. Hawaii, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
100 F. Supp. 2d 1265, 2000 U.S. Dist. LEXIS 9104, 2000 WL 854428, Counsel Stack Legal Research, https://law.counselstack.com/opinion/blowers-v-eli-lilly-co-hid-2000.